Samsung BioLogics Archives | Page 2 of 2 | Be Korea-savvy

S. Korea’s Biomedicine Exports Top US$1 Bln in 2016: Data

SEOUL, Jan. 18 (Korea Bizwire) – Biomedicine exports by South Korean pharmaceutical firms jumped more than 50 percent in 2016 from a year earlier to surpass the US$1 billion mark for the first time, data showed Wednesday.  Outbound shipments of locally manufactured biomedicines such as vaccines and genetic recombination drugs stood at US$1.44 billion last [...]

Mega IPOs May Help Shore up Sagging Stock Market

Mega IPOs May Help Shore up Sagging Stock Market

SEOUL, Nov. 3 (Korea Bizwire) — Samsung BioLogics, a biopharmaceutical unit of Samsung Group, and Doosan Bobcat Co., an affiliate of power equipment conglomerate Doosan Group, are set to make their market debuts this month, which some analysts say may help the local stock market recover from a recent market turmoil. Last week, Samsung BioLogics, [...]

Samsung BioLogics Set to Start IPO Process This Week

Samsung BioLogics Set to Start IPO Process This Week

SEOUL, Aug. 8 (Korea Bizwire) – Samsung BioLogics Co., a biosimilar firm affiliated with Samsung Group, will apply for preliminary approval this week for its initial public offering (IPO), estimated at around 3 trillion won (US$2.68 billion), South Korea’s bourse said Monday.  The firm, one of the world’s largest manufacturers of biosimilar medicine, plans to [...]

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

NEW YORK & SEOUL, South Korea, Apr. 22, 2014 (Korea Bizwire) – Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the [...]